{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T13:58:09Z","timestamp":1794751089323,"version":"4.9.1"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-00775"],"award-info":[{"award-number":["2022-00775"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["2017-0383"],"award-info":[{"award-number":["2017-0383"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2021-0293"],"award-info":[{"award-number":["FO2021-0293"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007625","name":"Cure Alzheimer\u2019s Fund","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish federal government under the ALF agreement"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Aging"],"DOI":"10.1038\/s43587-023-00403-3","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:01:28Z","timestamp":1684411288000},"page":"506-519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":514,"title":["Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-4193","authenticated-orcid":false,"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2192-1699","authenticated-orcid":false,"given":"Jeffrey","family":"Dage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"403_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure, M. A. & Dickson, D. W. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol. Neurodegener. 14, 32 (2019).","journal-title":"Mol. Neurodegener."},{"key":"403_CR2","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954\u2013963 (2021).","journal-title":"Nat. Med."},{"key":"403_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34129-4","volume":"13","author":"A Pichet Binette","year":"2022","unstructured":"Pichet Binette, A. et al. Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer\u2019s disease. Nat. Commun. 13, 6635 (2022).","journal-title":"Nat. Commun."},{"key":"403_CR4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"Vogel, J. W. et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat. Med. 27, 871\u2013881 (2021).","journal-title":"Nat. Med."},{"key":"403_CR5","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 9, 197\u2013210 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"403_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun, M. A. et al. Donanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 384, 1691\u20131704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"403_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"403_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","volume":"79","author":"WJ Jansen","year":"2022","unstructured":"Jansen, W. J. et al. Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol. 79, 228\u2013243 (2022).","journal-title":"JAMA Neurol."},{"key":"403_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1001\/jamaneurol.2018.3692","volume":"76","author":"R Smith","year":"2019","unstructured":"Smith, R., Wibom, M., Pawlik, D., Englund, E. & Hansson, O. Correlation of in vivo [18F]flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol. 76, 310\u2013317 (2019).","journal-title":"JAMA Neurol."},{"key":"403_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher, A. S. et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 77, 829\u2013839 (2020).","journal-title":"JAMA Neurol."},{"key":"403_CR11","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151\u20131162 (2018).","journal-title":"JAMA"},{"key":"403_CR12","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/alz.12356","volume":"17","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele, R. & Hansson, O. Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer\u2019s disease. Alzheimers Dement. 17, 1998\u20132008 (2021).","journal-title":"Alzheimers Dement."},{"key":"403_CR13","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. 28, 2381\u20132387 (2022).","journal-title":"Nat. Med."},{"key":"403_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack, C. R. Jr. et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"403_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze, S. et al. CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of Alzheimer disease. Ann. Clin. Transl. Neurol. 3, 154\u2013165 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"403_CR16","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson, O. et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 14, 1470\u20131481 (2018).","journal-title":"Alzheimers Dement."},{"key":"403_CR17","doi-asserted-by":"publisher","first-page":"e1137","DOI":"10.1212\/WNL.0000000000200040","volume":"98","author":"N Mattsson-Carlgren","year":"2022","unstructured":"Mattsson-Carlgren, N. et al. Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration. Neurology 98, e1137\u2013e1150 (2022).","journal-title":"Neurology"},{"key":"403_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1515\/cclm-2021-0651","volume":"60","author":"J Gobom","year":"2022","unstructured":"Gobom, J. et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin. Chem. Lab. Med. 60, 207\u2013219 (2022).","journal-title":"Clin. Chem. Lab. Med."},{"key":"403_CR19","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","volume":"85","author":"S Palmqvist","year":"2015","unstructured":"Palmqvist, S. et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85, 1240\u20131249 (2015).","journal-title":"Neurology"},{"key":"403_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow, K. & Zetterberg, H. Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J. Intern. Med. 284, 643\u2013663 (2018).","journal-title":"J. Intern. Med."},{"key":"403_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat. Commun. 11, 1683 (2020).","journal-title":"Nat. Commun."},{"key":"403_CR22","doi-asserted-by":"publisher","first-page":"e1681","DOI":"10.1212\/WNL.0000000000012727","volume":"97","author":"A Leuzy","year":"2021","unstructured":"Leuzy, A. et al. Comparing the clinical utility and diagnostic performance of CSF p-Tau181, p-Tau217, and p-Tau231 assays. Neurology 97, e1681\u2013e1694 (2021).","journal-title":"Neurology"},{"key":"403_CR23","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/alz.12236","volume":"17","author":"TK Karikari","year":"2021","unstructured":"Karikari, T. K. et al. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer\u2019s disease diagnosis. Alzheimers Dement. 17, 755\u2013767 (2021).","journal-title":"Alzheimers Dement."},{"key":"403_CR24","doi-asserted-by":"publisher","first-page":"e12921","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Suarez-Calvet","year":"2020","unstructured":"Suarez-Calvet, M. et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected. EMBO Mol. Med. 12, e12921 (2020).","journal-title":"EMBO Mol. Med."},{"key":"403_CR25","doi-asserted-by":"publisher","first-page":"e3026","DOI":"10.1212\/WNL.0000000000010814","volume":"95","author":"J Hanes","year":"2020","unstructured":"Hanes, J. et al. Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology 95, e3026\u2013e3035 (2020).","journal-title":"Neurology"},{"key":"403_CR26","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/alz.12415","volume":"18","author":"MM Mielke","year":"2022","unstructured":"Mielke, M. M. et al. Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimers Dement. 18, 602\u2013611 (2022).","journal-title":"Alzheimers Dement."},{"key":"403_CR27","doi-asserted-by":"publisher","first-page":"e2233","DOI":"10.1212\/WNL.0000000000009485","volume":"94","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. The implications of different approaches to define AT(N) in Alzheimer disease. Neurology 94, e2233\u2013e2244 (2020).","journal-title":"Neurology"},{"key":"403_CR28","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler, S. E. et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93, e1647\u2013e1659 (2019).","journal-title":"Neurology"},{"key":"403_CR29","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/brain\/aww015","volume":"139","author":"S Palmqvist","year":"2016","unstructured":"Palmqvist, S., Mattsson, N., Hansson, O. & Alzheimer\u2019s Disease Neuroimaging Initiative. Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography. Brain 139, 1226\u20131236 (2016).","journal-title":"Brain"},{"key":"403_CR30","doi-asserted-by":"publisher","first-page":"e11170","DOI":"10.15252\/emmm.201911170","volume":"11","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist, S. et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol. Med. 11, e11170 (2019).","journal-title":"EMBO Mol. Med."},{"key":"403_CR31","doi-asserted-by":"publisher","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer\u2019s disease. Sci. Adv. 6, eaaz2387 (2020).","journal-title":"Sci. Adv."},{"key":"403_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze, S. et al. Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 78, 149\u2013156 (2021).","journal-title":"JAMA Neurol."},{"key":"403_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac329","author":"C Groot","year":"2022","unstructured":"Groot, C. et al. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals. Brain https:\/\/doi.org\/10.1093\/brain\/awac329 (2022).","journal-title":"Brain"},{"key":"403_CR34","doi-asserted-by":"crossref","unstructured":"Bastiaansen, A. E. M. et al. Autoimmune encephalitis resembling dementia syndromes. Neurol. Neuroimmunol. Neuroinflamm. 8, e1039 (2021).","DOI":"10.1212\/NXI.0000000000001039"},{"key":"403_CR35","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/sj.mp.4001220","volume":"8","author":"M Riemenschneider","year":"2003","unstructured":"Riemenschneider, M. et al. Phospho-tau\/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt\u2013Jakob disease from other dementias. Mol. Psychiatry 8, 343\u2013347 (2003).","journal-title":"Mol. Psychiatry"},{"key":"403_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0304-3940(00)01697-9","volume":"297","author":"C Hesse","year":"2001","unstructured":"Hesse, C. et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett. 297, 187\u2013190 (2001).","journal-title":"Neurosci. Lett."},{"key":"403_CR37","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1212\/01.wnl.0000242732.06714.0f","volume":"67","author":"M Ost","year":"2006","unstructured":"Ost, M. et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 67, 1600\u20131604 (2006).","journal-title":"Neurology"},{"key":"403_CR38","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14, 577\u2013589 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"403_CR39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische, O. et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat. Med. 25, 277\u2013283 (2019).","journal-title":"Nat. Med."},{"key":"403_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12907","author":"G Salvado","year":"2023","unstructured":"Salvado, G. et al. Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: a multi-cohort study. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12907 (2023).","journal-title":"Alzheimers Dement."},{"key":"403_CR41","doi-asserted-by":"publisher","unstructured":"Salvad\u00f3, G. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol. Med. https:\/\/doi.org\/10.15252\/emmm.202217123 (2023).","DOI":"10.15252\/emmm.202217123"},{"key":"403_CR42","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura, A. et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature 554, 249\u2013254 (2018).","journal-title":"Nature"},{"key":"403_CR43","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod, V. et al. Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 13, 841\u2013849 (2017).","journal-title":"Alzheimers Dement."},{"key":"403_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze, S. et al. Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease. Sci. Rep. 6, 26801 (2016).","journal-title":"Sci. Rep."},{"key":"403_CR45","doi-asserted-by":"publisher","first-page":"e688","DOI":"10.1212\/WNL.0000000000013211","volume":"98","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Validation of plasma amyloid-\u03b2 42\/40 for detecting Alzheimer disease amyloid plaques. Neurology 98, e688\u2013e699 (2022).","journal-title":"Neurology"},{"key":"403_CR46","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","volume":"76","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist, S. et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related \u03b2-amyloid status. JAMA Neurol. 76, 1060\u20131069 (2019).","journal-title":"JAMA Neurol."},{"key":"403_CR47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13024-021-00451-6","volume":"16","author":"T West","year":"2021","unstructured":"West, T. et al. A blood-based diagnostic test incorporating plasma A\u03b242\/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Mol. Neurodegener. 16, 30 (2021).","journal-title":"Mol. Neurodegener."},{"key":"403_CR48","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze, S. et al. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol. 78, 1375\u20131382 (2021).","journal-title":"JAMA Neurol."},{"key":"403_CR49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jalz.2008.10.004","volume":"5","author":"AE Roher","year":"2009","unstructured":"Roher, A. E. et al. Amyloid \u03b2 peptides in human plasma and tissues and their significance for Alzheimer\u2019s disease. Alzheimers Dement. 5, 18\u201329 (2009).","journal-title":"Alzheimers Dement."},{"key":"403_CR50","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke, M. M. et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 14, 989\u2013997 (2018).","journal-title":"Alzheimers Dement."},{"key":"403_CR51","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Plasma p-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat. Med. 26, 379\u2013386 (2020).","journal-title":"Nat. Med."},{"key":"403_CR52","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422\u2013433 (2020).","journal-title":"Lancet Neurol."},{"key":"403_CR53","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen, E. H. et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat. Med. 26, 387\u2013397 (2020).","journal-title":"Nat. Med."},{"key":"403_CR54","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"403_CR55","doi-asserted-by":"crossref","unstructured":"Barthelemy, N. R., Horie, K., Sato, C. & Bateman, R. J. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J. Exp. Med. 217, e20200861 (2020).","DOI":"10.1084\/jem.20200861"},{"key":"403_CR56","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 141, 709\u2013724 (2021).","journal-title":"Acta Neuropathol."},{"key":"403_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac333","author":"S Janelidze","year":"2022","unstructured":"Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain https:\/\/doi.org\/10.1093\/brain\/awac333 (2022).","journal-title":"Brain"},{"key":"403_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12841","author":"NJ Ashton","year":"2022","unstructured":"Ashton, N. J. et al. Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12841 (2022).","journal-title":"Alzheimers Dement."},{"key":"403_CR59","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke, M. M. et al. Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 78, 1108\u20131117 (2021).","journal-title":"JAMA Neurol."},{"key":"403_CR60","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","volume":"13","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy, S. et al. Clinical and analytical comparison of six Simoa assays for plasma p-tau isoforms p-tau181, p-tau217, and p-tau231. Alzheimers Res. Ther. 13, 198 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"403_CR61","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton, N. J. et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat. Med. 28, 2555\u20132562 (2022).","journal-title":"Nat. Med."},{"key":"403_CR62","first-page":"1797","volume":"28","author":"M Mila-Aloma","year":"2022","unstructured":"Mila-Aloma, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 28, 1797\u20131801 (2022).","journal-title":"Nat. Med."},{"key":"403_CR63","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2022","unstructured":"Therriault, J. et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 80, 188\u2013199 (2022).","journal-title":"JAMA Neurol."},{"key":"403_CR64","doi-asserted-by":"publisher","first-page":"e14022","DOI":"10.15252\/emmm.202114022","volume":"13","author":"N Mattsson-Carlgren","year":"2021","unstructured":"Mattsson-Carlgren, N. et al. Soluble p-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol. Med. 13, e14022 (2021).","journal-title":"EMBO Mol. Med."},{"key":"403_CR65","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.neuron.2018.04.035","volume":"98","author":"C Sato","year":"2018","unstructured":"Sato, C. et al. Tau kinetics in neurons and the human central nervous system. Neuron 98, 861\u2013864 (2018).","journal-title":"Neuron"},{"key":"403_CR66","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00401-021-02400-5","volume":"143","author":"SA Kaeser","year":"2022","unstructured":"Kaeser, S. A. et al. CSF p-tau increase in response to A\u03b2-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles. Acta Neuropathol. 143, 287\u2013290 (2022).","journal-title":"Acta Neuropathol."},{"key":"403_CR67","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/brain\/awaa373","volume":"144","author":"K Horie","year":"2021","unstructured":"Horie, K., Barthelemy, N. R., Sato, C. & Bateman, R. J. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer\u2019s disease. Brain 144, 515\u2013527 (2021).","journal-title":"Brain"},{"key":"403_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun. 12, 3400 (2021).","journal-title":"Nat. Commun."},{"key":"403_CR69","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","volume":"3","author":"M Gisslen","year":"2016","unstructured":"Gisslen, M. et al. Plasma concentration of the neurofilament light protein (NfL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 3, 135\u2013140 (2016).","journal-title":"EBioMedicine"},{"key":"403_CR70","doi-asserted-by":"crossref","unstructured":"Rodrigues, F. B. et al. Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington\u2019s disease. Sci. Transl. Med. 12, eabc2888 (2020).","DOI":"10.1126\/scitranslmed.abc2888"},{"key":"403_CR71","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13195-020-00682-7","volume":"12","author":"IMW Verberk","year":"2020","unstructured":"Verberk, I. M. W. et al. Combination of plasma amyloid \u03b2(1\u201342\/1\u201340) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res. Ther. 12, 118 (2020).","journal-title":"Alzheimers Res. Ther."},{"key":"403_CR72","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira, J. B. et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain 144, 3505\u20133516 (2021).","journal-title":"Brain"},{"key":"403_CR73","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet, A. L. et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 78, 1471\u20131483 (2021).","journal-title":"JAMA Neurol."},{"key":"403_CR74","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","volume":"2","author":"IMW Verberk","year":"2021","unstructured":"Verberk, I. M. W. et al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Healthy Longev. 2, e87\u2013e95 (2021).","journal-title":"Lancet Healthy Longev."},{"key":"403_CR75","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","volume":"13","author":"C Cicognola","year":"2021","unstructured":"Cicognola, C. et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res. Ther. 13, 68 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"403_CR76","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/jnnp-2019-321954","volume":"91","author":"C Heller","year":"2020","unstructured":"Heller, C. et al. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 91, 263\u2013270 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"403_CR77","unstructured":"Brum, W. S. et al. A two-step workflow based on plasma p-tau217 to screen for A\u03b2 pathology with further confirmatory testing only in uncertain cases. Nat. Aging (in the press)."},{"key":"403_CR78","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/alz.12395","volume":"18","author":"S Janelidze","year":"2022","unstructured":"Janelidze, S. et al. Detecting amyloid positivity in early Alzheimer\u2019s disease using combinations of plasma A\u03b242\/A\u03b240 and p-tau. Alzheimers Dement. 18, 283\u2013293 (2022).","journal-title":"Alzheimers Dement."},{"key":"403_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12751","author":"S Palmqvist","year":"2022","unstructured":"Palmqvist, S. et al. An accurate fully automated panel of plasma biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12751 (2022).","journal-title":"Alzheimers Dement."},{"key":"403_CR80","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","volume":"18","author":"TK Karikari","year":"2022","unstructured":"Karikari, T. K. et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat. Rev. Neurol. 18, 400\u2013418 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"403_CR81","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 21, 66\u201377 (2022).","journal-title":"Lancet Neurol."},{"key":"403_CR82","doi-asserted-by":"publisher","first-page":"e14408","DOI":"10.15252\/emmm.202114408","volume":"14","author":"A Leuzy","year":"2022","unstructured":"Leuzy, A. et al. Blood-based biomarkers for Alzheimer\u2019s disease. EMBO Mol. Med. 14, e14408 (2022).","journal-title":"EMBO Mol. Med."},{"key":"403_CR83","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/alz.12706","volume":"19","author":"NC Cullen","year":"2023","unstructured":"Cullen, N. C. et al. Test\u2013retest variability of plasma biomarkers in Alzheimer\u2019s disease and its effects on clinical prediction models. Alzheimers Dement. 19, 797\u2013806 (2023).","journal-title":"Alzheimers Dement."},{"key":"403_CR84","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke, M. M. et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat. Med. 28, 1398\u20131405 (2022).","journal-title":"Nat. Med."},{"key":"403_CR85","doi-asserted-by":"publisher","unstructured":"Janelidze, S., Barth\u00e9lemy, N. R., He, Y., Bateman, R. J. & Hansson, O. Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using a phosphorylated tau to total tau ratio. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2023.0199 (2023).","DOI":"10.1001\/jamaneurol.2023.0199"},{"key":"403_CR86","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12801","author":"C Rabe","year":"2022","unstructured":"Rabe, C. et al. Clinical performance and robustness evaluation of plasma amyloid-\u03b242\/40 prescreening. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12801 (2022).","journal-title":"Alzheimers Dement."},{"key":"403_CR87","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson, O. et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 18, 2669\u20132686 (2022).","journal-title":"Alzheimers Dement."},{"key":"403_CR88","doi-asserted-by":"crossref","first-page":"e12189","DOI":"10.1002\/trc2.12189","volume":"7","author":"A Mank","year":"2021","unstructured":"Mank, A. et al. Identifying relevant outcomes in the progression of Alzheimer\u2019s disease; what do patients and care partners want to know about prognosis? Alzheimers Dement. 7, e12189 (2021).","journal-title":"Alzheimers Dement."},{"key":"403_CR89","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","volume":"26","author":"TK Karikari","year":"2021","unstructured":"Karikari, T. K. et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative. Mol. Psychiatry 26, 429\u2013442 (2021).","journal-title":"Mol. Psychiatry"},{"key":"403_CR90","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist, S. et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat. Med. 27, 1034\u20131042 (2021).","journal-title":"Nat. Med."},{"key":"403_CR91","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","volume":"1","author":"N Cullen","year":"2021","unstructured":"Cullen, N. et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat. Aging 1, 114\u2013123 (2021).","journal-title":"Nat. Aging"},{"key":"403_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12875","author":"R Smith","year":"2022","unstructured":"Smith, R. et al. Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12875 (2022).","journal-title":"Alzheimers Dement."},{"key":"403_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12754","author":"SE Schindler","year":"2022","unstructured":"Schindler, S. E. et al. Using Alzheimer\u2019s disease blood tests to accelerate clinical trial enrollment. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12754 (2022).","journal-title":"Alzheimers Dement."},{"key":"403_CR94","doi-asserted-by":"crossref","unstructured":"Cullen, N. et al. Plasma amyloid-\u03b242\/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer\u2019s disease. Brain Commun. 5, fcad015 (2023).","DOI":"10.1093\/braincomms\/fcad015"},{"key":"403_CR95","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/WNL.0000000000007831","volume":"93","author":"PS Insel","year":"2019","unstructured":"Insel, P. S. et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology 93, e322\u2013e333 (2019).","journal-title":"Neurology"},{"key":"403_CR96","doi-asserted-by":"crossref","first-page":"e662","DOI":"10.1212\/WNL.0000000000011707","volume":"96","author":"LM van der Kall","year":"2021","unstructured":"van der Kall, L. M. et al. Association of \u03b2-amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals. Neurology 96, e662\u2013e670 (2021).","journal-title":"Neurology"},{"key":"403_CR97","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","volume":"317","author":"MC Donohue","year":"2017","unstructured":"Donohue, M. C. et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 317, 2305\u20132316 (2017).","journal-title":"JAMA"},{"key":"403_CR98","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.5272","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren, N. et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5272 (2023).","journal-title":"JAMA Neurol."},{"key":"403_CR99","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","volume":"78","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele, R. et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 78, 961\u2013971 (2021).","journal-title":"JAMA Neurol."},{"key":"403_CR100","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2021.4654","volume":"79","author":"A Leuzy","year":"2022","unstructured":"Leuzy, A. et al. Biomarker-based prediction of longitudinal tau positron emission tomography in Alzheimer disease. JAMA Neurol. 79, 149\u2013158 (2022).","journal-title":"JAMA Neurol."},{"key":"403_CR101","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/WAD.0b013e3181a6bebc","volume":"23","author":"A Bradford","year":"2009","unstructured":"Bradford, A., Kunik, M. E., Schulz, P., Williams, S. P. & Singh, H. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis. Assoc. Disord. 23, 306\u2013314 (2009).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"403_CR102","unstructured":"US Food and Drug Administration. Surrogate Endpoint Resources for Drug and Biologic Development https:\/\/www.fda.gov\/drugs\/development-resources\/surrogate-endpoint-resources-drug-and-biologic-development (2018)."},{"key":"403_CR103","doi-asserted-by":"publisher","first-page":"e0274565","DOI":"10.1371\/journal.pone.0274565","volume":"17","author":"L Ning","year":"2022","unstructured":"Ning, L. & Wang, B. Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: a systematic review and meta-analysis. PLoS ONE 17, e0274565 (2022).","journal-title":"PLoS ONE"},{"key":"403_CR104","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","volume":"73","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg, H. et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 73, 60\u201367 (2016).","journal-title":"JAMA Neurol."},{"key":"403_CR105","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K. & Alzheimer\u2019s Disease Neuroimaging, I. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 74, 557\u2013566 (2017).","journal-title":"JAMA Neurol."},{"key":"403_CR106","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto, G. et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81, 857\u2013870 (2017).","journal-title":"Ann. Neurol."},{"key":"403_CR107","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1212\/WNL.0000000000009559","volume":"95","author":"M Benatar","year":"2020","unstructured":"Benatar, M. et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95, e59\u2013e69 (2020).","journal-title":"Neurology"},{"key":"403_CR108","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1038\/s41591-022-01942-9","volume":"28","author":"AM Staffaroni","year":"2022","unstructured":"Staffaroni, A. M. et al. Temporal order of clinical and biomarker changes in familial frontotemporal dementia. Nat. Med. 28, 2194\u20132206 (2022).","journal-title":"Nat. Med."},{"key":"403_CR109","doi-asserted-by":"publisher","first-page":"e1201","DOI":"10.1212\/WNL.0000000000009097","volume":"94","author":"B Delcoigne","year":"2020","unstructured":"Delcoigne, B. et al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology 94, e1201\u2013e1212 (2020).","journal-title":"Neurology"},{"key":"403_CR110","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","volume":"266","author":"B Olsson","year":"2019","unstructured":"Olsson, B. et al. NfL is a marker of treatment response in children with SMA treated with nusinersen. J. Neurol. 266, 2129\u20132136 (2019).","journal-title":"J. Neurol."},{"key":"403_CR111","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","volume":"27","author":"S Salloway","year":"2021","unstructured":"Salloway, S. et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Nat. Med. 27, 1187\u20131196 (2021).","journal-title":"Nat. Med."},{"key":"403_CR112","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson, C. J. et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res. Ther. 13, 80 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"403_CR113","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","volume":"79","author":"MJ Pontecorvo","year":"2022","unstructured":"Pontecorvo, M. J. et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 79, 1250\u20131259 (2022).","journal-title":"JAMA Neurol."},{"key":"403_CR114","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archgenpsychiatry.2011.155","volume":"69","author":"P Buchhave","year":"2012","unstructured":"Buchhave, P. et al. Cerebrospinal fluid levels of \u03b2-amyloid 1\u201342, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry 69, 98\u2013106 (2012).","journal-title":"Arch. Gen. Psychiatry"},{"key":"403_CR115","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/gps.2353","volume":"25","author":"K Samgard","year":"2010","unstructured":"Samgard, K. et al. Cerebrospinal fluid total tau as a marker of Alzheimer\u2019s disease intensity. Int. J. Geriatr. Psychiatry 25, 403\u2013410 (2010).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"403_CR116","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain 143, 3234\u20133241 (2020).","journal-title":"Brain"},{"key":"403_CR117","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/acn3.51253","volume":"8","author":"O Hansson","year":"2021","unstructured":"Hansson, O. et al. Plasma phosphorylated tau181 and neurodegeneration in Alzheimer\u2019s disease. Ann. Clin. Transl. Neurol. 8, 259\u2013265 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"403_CR118","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/brain\/awaa399","volume":"144","author":"A Moscoso","year":"2021","unstructured":"Moscoso, A. et al. Time course of phosphorylated-tau181 in blood across the Alzheimer\u2019s disease spectrum. Brain 144, 325\u2013339 (2021).","journal-title":"Brain"},{"key":"403_CR119","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13024-017-0152-5","volume":"12","author":"E Portelius","year":"2017","unstructured":"Portelius, E. et al. Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid \u03b2 clearance pathway. Mol. Neurodegener. 12, 18 (2017).","journal-title":"Mol. Neurodegener."},{"key":"403_CR120","doi-asserted-by":"crossref","unstructured":"Yanamandra, K. et al. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Sci. Transl. Med. 9 eaal2029 (2017).","DOI":"10.1126\/scitranslmed.aal2029"},{"key":"403_CR121","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cca.2016.05.014","volume":"467","author":"J Kuhlmann","year":"2017","unstructured":"Kuhlmann, J. et al. CSF A\u03b21\u201342\u2014an excellent but complicated Alzheimer\u2019s biomarker\u2014a route to standardisation. Clin. Chim. Acta 467, 27\u201333 (2017).","journal-title":"Clin. Chim. Acta"},{"key":"403_CR122","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/alz.12145","volume":"16","author":"S Boulo","year":"2020","unstructured":"Boulo, S. et al. First amyloid \u03b21\u201342 certified reference material for re-calibrating commercial immunoassays. Alzheimers Dement. 16, 1493\u20131503 (2020).","journal-title":"Alzheimers Dement."},{"key":"403_CR123","first-page":"e12242","volume":"13","author":"J Pannee","year":"2021","unstructured":"Pannee, J. et al. The global Alzheimer\u2019s Association round robin study on plasma amyloid \u03b2 methods. Alzheimers Dement. 13, e12242 (2021).","journal-title":"Alzheimers Dement."},{"key":"403_CR124","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1515\/cclm-2018-0147","volume":"56","author":"U Andreasson","year":"2018","unstructured":"Andreasson, U. et al. Commutability of the certified reference materials for the standardization of \u03b2-amyloid 1\u201342 assay in human cerebrospinal fluid: lessons for tau and \u03b2-amyloid 1\u201340 measurements. Clin. Chem. Lab. Med. 56, 2058\u20132066 (2018).","journal-title":"Clin. Chem. Lab. Med."},{"key":"403_CR125","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/alz.12316","volume":"17","author":"O Hansson","year":"2021","unstructured":"Hansson, O. et al. The Alzheimer\u2019s Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau. Alzheimers Dement. 17, 1575\u20131582 (2021).","journal-title":"Alzheimers Dement."},{"key":"403_CR126","first-page":"291","volume":"11","author":"M Rozga","year":"2019","unstructured":"Rozga, M., Bittner, T., Batrla, R. & Karl, J. Preanalytical sample handling recommendations for Alzheimer\u2019s disease plasma biomarkers. Alzheimers Dement. 11, 291\u2013300 (2019).","journal-title":"Alzheimers Dement."},{"key":"403_CR127","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","volume":"18","author":"IMW Verberk","year":"2021","unstructured":"Verberk, I. M. W. et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease-related blood-based biomarkers: results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group. Alzheimers Dement. 18, 1484\u20131497 (2021).","journal-title":"Alzheimers Dement."},{"key":"403_CR128","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3233\/JAD-221118","volume":"92","author":"CN Winston","year":"2023","unstructured":"Winston, C. N. et al. Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer\u2019s disease. J. Alzheimers Dis. 92, 95\u2013107 (2023).","journal-title":"J. Alzheimers Dis."},{"key":"403_CR129","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12897","author":"A Leuzy","year":"2023","unstructured":"Leuzy, A. et al. Robustness of CSF A\u03b242\/40 and A\u03b242\/p-tau181 measured using fully automated immunoassays to detect AD-related outcomes. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12897 (2023).","journal-title":"Alzheimers Dement."},{"key":"403_CR130","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-021-00942-0","volume":"14","author":"AL Benedet","year":"2022","unstructured":"Benedet, A. L. et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimers Res. Ther. 14, 26 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"403_CR131","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","volume":"17","author":"H Hampel","year":"2021","unstructured":"Hampel, H. et al. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat. Rev. Neurol. 17, 580\u2013589 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"403_CR132","first-page":"fcac174","volume":"4","author":"J Simren","year":"2022","unstructured":"Simren, J. et al. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5\u201390 years. Brain Commun. 4, fcac174 (2022).","journal-title":"Brain"},{"key":"403_CR133","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/alz.12466","volume":"18","author":"JA Syrjanen","year":"2022","unstructured":"Syrjanen, J. A. et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 18, 1128\u20131140 (2022).","journal-title":"Alzheimers Dement."},{"key":"403_CR134","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12787","author":"A Pichet Binette","year":"2022","unstructured":"Pichet Binette, A. et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12787 (2022).","journal-title":"Alzheimers Dement."},{"key":"403_CR135","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","volume":"4","author":"GM Sullivan","year":"2012","unstructured":"Sullivan, G. M. & Feinn, R. Using effect size\u2014or why the P value is not enough. J. Grad. Med. Educ. 4, 279\u2013282 (2012).","journal-title":"J. Grad. Med. Educ."},{"key":"403_CR136","first-page":"302","volume":"74","author":"E Lim","year":"2015","unstructured":"Lim, E., Miyamura, J. & Chen, J. J. Racial\/ethnic-specific reference intervals for common laboratory tests: a comparison among Asians, Blacks, Hispanics, and white. Hawaii J. Med. Public Health 74, 302\u2013310 (2015).","journal-title":"Hawaii J. Med. Public Health"},{"key":"403_CR137","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/alz.12301","volume":"17","author":"AM Brickman","year":"2021","unstructured":"Brickman, A. M. et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 17, 1353\u20131364 (2021).","journal-title":"Alzheimers Dement."},{"key":"403_CR138","first-page":"e12315","volume":"14","author":"C Windon","year":"2022","unstructured":"Windon, C. et al. Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI. Alzheimers Dement. 14, e12315 (2022).","journal-title":"Alzheimers Dement."},{"key":"403_CR139","doi-asserted-by":"publisher","first-page":"e228392","DOI":"10.1001\/jamanetworkopen.2022.8392","volume":"5","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. Assessment of a plasma amyloid probability score to estimate amyloid positron emission tomography findings among adults with cognitive impairment. JAMA Netw. Open 5, e228392 (2022).","journal-title":"JAMA Netw. Open"}],"container-title":["Nature Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43587-023-00403-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-023-00403-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-023-00403-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T05:17:36Z","timestamp":1702444656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43587-023-00403-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":139,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["403"],"URL":"https:\/\/doi.org\/10.1038\/s43587-023-00403-3","relation":{},"ISSN":["2662-8465"],"issn-type":[{"value":"2662-8465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"assertion":[{"value":"22 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.H. has acquired research support (for the institution) from ADx, Avid Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy and\/or speaker fees from AC Immune, Amylyx, ALZpath, BioArctic, Biogen, Cerveau, Eisai, Fujirebio, Genentech, Novartis, Roche and Siemens. K.B. has served as a consultant on advisory boards or on data-monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD\u2013Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics and Siemens Healthineers and is a cofounder of Brain Biomarker Solutions in Gothenburg (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. H.Z. has served on scientific advisory boards and\/or as a consultant for AbbVie, Acumen, Alector, Alzinova, ALZpath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, NervGen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, AlzeCure, Biogen and Roche; and is a cofounder of Brain Biomarker Solutions in Gothenburg (BBS), which is a part of the GU Ventures Incubator Program (outside the work presented in this paper). J.D. is an inventor on patents or patent applications of Eli Lilly relating to the assays, methods, reagents and\/or compositions of matter related to measurement of p-tau217. J.D. has served as a consultant for AbbVie, Genotix Biotechnologies, Gates Ventures, Karuna Therapeutics, ALZpath and Cognito Therapeutics and received research support from ADx NeuroSciences, Fujirebio, ALZpath, Roche Diagnostics and Eli Lilly in the past 2 years. J.D. has received speaker fees from Eli Lilly.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}